Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

NCT00787384 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Hypereosinophilic Syndrome
Chronic Eosinophilic Leukemia
Chronic Idiopathic Hypereosinophilia

Interventions

DRUG: Imatinib

Sponsor

Northern Italy Leukemia Group